HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ICUI
ICU Medical, Inc.
ICUI's fundamentals are mixed, but it looks expensive: trading at 74x earnings, above its usual 52x. Analysts expect strong earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ICUI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
ICUI's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ICUI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $177 | — |
| Cheap | 46x | $110 | -38% |
| Fair | 52x | $124 | -30% |
| Current | 74x | $177 | — |
| Expensive | 136x | $325 | +83% |
Historical ranges are pointers, not guarantees.
ICUI's PE is in its expensive range at 74x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ICUI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
ICUI has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ICUI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.19 | +283% |
| Q3 2026 | $2.40 | +$2.71 |
| Q2 2026 | $1.19 | +$2.71 |
| Q1 2026 | $1.86 | +$5.69 |
| Q4 2025 | $0.03 | +$4.86 |
| Q3 2025 | -$0.31 | +$4.26 |
| Q2 2025 | -$1.52 | +$1.40 |
| Q1 2025 | -$3.83 | -$1.38 |
| Q4 2024 | -$4.83 | -$3.60 |
ICUI has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ICUI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ICUI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $560.4M | +4.4% |
| Q2 2026 | $551.7M | +0.5% |
| Q1 2026 | $530.2M | -12% |
| Q4 2025 | $540.7M | -14% |
| Q3 2025 | $537M | -8.9% |
| Q2 2025 | $548.9M | -8% |
| Q1 2025 | $604.7M | +6.7% |
| Q4 2024 | $629.8M | +7.1% |
ICUI's revenue is down over the past year, though its latest quarter was up: $560M last quarter, up 4.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.3% | +6.8 points |
| Q2 2026 | 7.1% | +5.2 points |
| Q1 2026 | 2.6% | +0.4 points |
| Q4 2025 | 1% | -4.9 points |
| Q3 2025 | 2.5% | +1.1 points |
| Q2 2025 | 1.9% | +0.6 points |
| Q1 2025 | 2.1% | +4 points |
| Q4 2024 | 6% | +8.1 points |
ICUI has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ICUI on cash flow, with more consistent year-over-year improvement.
ICUI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $83.4M | +202% |
| Q2 2026 | $61.6M | +$70.1M |
| Q1 2026 | $27.6M | -25% |
| Q4 2025 | $36M | +123% |
| Q3 2025 | $27.6M | +71% |
| Q2 2025 | -$8.5M | -114% |
| Q1 2025 | $36.7M | +23% |
| Q4 2024 | $16.1M | -74% |
ICUI generated $209M in free cash flow over the past year, up 190% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ICUI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ICUI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +101K shares |
| 1 year | +1.9% | +459K shares |
| 3 years | +3.2% | +777K shares |
| 5 years | +16% | +3.4M shares |
| Available history | +17% | +3.6M shares |
ICUI has 25M diluted shares, up 1.9% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ICUI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.7x | Moderate |
| Q2 2026 | 3.4x | Elevated |
| Q1 2026 | 4.1x | High |
| Q4 2025 | 4.0x | High |
| Q3 2025 | 3.7x | Elevated |
| Q2 2025 | 3.7x | Elevated |
| Q1 2025 | 4.5x | High |
| Q4 2024 | 4.9x | High |
ICUI's net debt is about 2.7 years of its operating earnings (EBITDA), down from 3.6 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ICUI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.4 | Neutral |
| Stochastic | 49.5 | Neutral |
ICUI's weekly RSI is 62 (neutral) and its Stochastic is 49 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ICUI PE vs Healthcare Sector
| Metric | ICUI | Sector median | Relative |
|---|---|---|---|
| PE | 74x | 26x | 186% above |
| PE % | 70 | 29 | 41 pts above |
ICUI is trading at 74x earnings, a 186% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ICUI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $165.9 | 6.9% above |
| 20 week MA | $166.1 | 6.7% above |
| 50 week MA | $149.5 | 19% above |
| 100 week MA | $143.8 | 23% above |
| 200 week MA | $141.8 | 25% above |
ICUI has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
ICUI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $186.2 | $211.7 | +14% |
| 2021 | $211.7 | $235.7 | +11% |
| 2022 | $235.7 | $156.0 | -34% |
| 2023 | $156.0 | $99.7 | -36% |
| 2024 | $99.7 | $154.5 | +55% |
| 2025 | $154.5 | $147.9 | -4.3% |
| 2026 YTD | $147.9 | $177.3 | +20% |
ICUI has the edge over HIMS on returns for 2026, with the stronger performance.